Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab Treatment Extension Study in Multiple Myeloma
NCT05669989Phase 2
Key facts
- Status
- Enrolling by invitation
- Start
- Apr 2023
- Primary completion
- Nov 2028
- Countries
- 17
- Sponsor
- Sanofi
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Drugs
- isatuximab
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by Sanofi. Primary endpoint: Number of participants with treatment-emergent adverse events at 42 months. Started Apr 2023; status: enrolling by invitation.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Isatuximab
Participants will receive isatuximab as monotherapy or in a combination regimen, according to the treatment the participant received on the parental protocol.
03
Who it enrols
Adult patients with multiple myeloma who completed a parental isatuximab study, are still benefiting from isatuximab, have no evidence of progressive disease, and have recovered from prior therapy toxicities.
04
Endpoints
Primary
Number of participants with treatment-emergent adverse events
Beyond the preview
Go deeper on NCT05669989.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669989.